Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395639 | 1.00 | KDM4E (0.69) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4984856 | 0.86 | KDM4E (0.67) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9984709 | 0.83 | TGFBR1 (0.69) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9985663 | 0.83 | TGFBR1 (0.69) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4437350 | 0.82 | MAPT (1.00) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4437351 | 0.82 | MAPT (1.00) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL3923962 | 0.82 | MAPT (1.00) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL149212 | 0.82 | MAPT (1.00) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL5292 | 0.82 | MAPT (1.00) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL3688241 | 0.82 | MAPT (1.00) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021034298-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CHRONIC HYPOXEMIA AND DYSPNEA | MARTIN ALAIN (US) | 2021-02-25 | — | — | WO | claimed |
| US-20180243246-A1 | Compositions and Methods for the Treatment and Prevention of Chronic Hypoxemia and Dyspnea. | CELLULAR SCIENCES, INC. | 2018-08-30 | — | — | US | claimed |
| EP-1183022-B1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN NASAL AND SINUS DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2010-12-29 | — | — | EP | claimed |
| EP-1429712-B1 | METHOD FOR TREATING BRONCHIAL CONSTRICTION AND BRONCHOSPASM | CELLULAR SCIENCES INC (US) | 2008-10-15 | — | — | EP | claimed |
| US-12611389-B1 | Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage | CELLULAR SCIENCES, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-11628186-B2 | Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the flu | CELLULAR SCIENCES, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11458114-B2 | Methods and compositions for enhancing synthesis secretion and transport of collagen to increase wound strength | North Cell Pharmaceuticals, Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11311505-B2 | Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts | CELLULAR SCIENCES, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022060397-A1 | METHOD AND COMPOSITION FOR THE REDUCTION OF VIRAL REPLICATION, DURATION AND SPREAD OF THE COVID-19 AND THE FLU | MARTIN ALAIN (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20210361604-A1 | Methods and Compositions For Enhancing Synthesis Secretion and Transport of Collagen to Increase Wound Strength | North Cell Pharmaceuticals, Inc. | 2021-11-25 | — | — | US | disclosed |
| WO-2021040673-A1 | METHODS FOR THE TREATMENT OF CHRONIC HYPOXEMIA AND INHIBITING LUNG FIBROSIS IN PATIENTS WITH PULMONARY FIBROSIS WITH AND WITHOUT COPD | MARTIN ALAIN (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021034298-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CHRONIC HYPOXEMIA AND DYSPNEA | MARTIN ALAIN (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1692107-A4 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1429712-B1 | METHOD FOR TREATING BRONCHIAL CONSTRICTION AND BRONCHOSPASM | CELLULAR SCIENCES INC (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1971340-A2 | NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007075542-A2 | NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1692107-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005060603-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-5607974-A | ADMINISTERING N-ACETYLCYSTEINE, AIDS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1997-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611389-B1 | Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage | CX3CR1, CHRM3, CHRM2 | KDM4E 3235/4885MAPT 364/4885THRB 244/4885 |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | KDM4E 2405/4885MAPT 3734/4885THRB 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.